Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, has announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of US$3.50 per share. The total gross proceeds to the company from the offering are expected to be approximately US$80.5 million, before deducting underwriting discounts and commissions and offering expenses payable by the company. All of the common stock is being offered by the company. The offering is expected to close on August 17, 2026, subject to customary closing conditions. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 3,450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Latham & Watkins LLP represents Zentalis in the offering with a corporate team led by partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Rachel Moore, Kan Ni, and Olivia Wagner.